Clinical Trial: A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional




Official Title: A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma

Brief Summary:

This research study is studying a pair of immunotherapies as a possible treatment for malignant pleural mesothelioma.

The drugs involved in this study are:

  • Durvalumab
  • Tremelimumab